Get started
Author

Dagmar Busse

Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin
1996 · M F Fromm, D Busse, et al. · Hepatology · 278
PDF
Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity
2000 · Dagmar Busse, Rachel S. Doughty, et al. · Journal of Biological Chemistry · 204
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
2001 · A E Lenferink, D Busse, et al. · PubMed · 178
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency
2002 · Marion Haubitz, Frank Bohnenstengel, et al. · Kidney International · 175
Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.
1997 · D Busse, F W Busch, et al. · Journal of Clinical Oncology · 107
Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans
1995 · Dagmar Busse, Jose Cosme, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 105
Gut wall metabolism of verapamil in older people: effects of rifampicin‐mediated enzyme induction
1998 · Martin F. Fromm, Karin Dilger, et al. · British Journal of Clinical Pharmacology · 50
PDF
Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism
1999 · Dagmar Busse, Friedrich W. Busch, et al. · Cancer Chemotherapy and Pharmacology · 42
Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance
2001 · Dagmar Busse, F. Michael Yakes, et al. · Seminars in Oncology · 39
HER-2/neu (erbB-2) and the cell cycle.
2000 · D Busse, R S Doughty, et al. · PubMed · 32
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study
2006 · Dagmar Busse, Silke Templin, et al. · European Journal of Clinical Pharmacology · 28
Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin???s Lymphoma and its Effect on Myelotoxicity
2007 · Stefan Wilde, Alexander Jetter, et al. · Clinical Pharmacokinetics · 19
Disposition and pharmacologic effects of R/S‐verapamil in patients with chronic atrial fibrillation: An investigation comparing single and multiple dosing
2001 · Dagmar Busse, Martin F. Fromm, et al. · Clinical Pharmacology & Therapeutics · 11
Population pharmacokinetics of cyclo- phosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy
2002 · S. Wilde, A. Jetter, et al. · International Journal of Clinical Pharmacology and Therapeutics · 9
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing
2011 · Kathrin Koucky, Axel Wein, et al. · Medical Science Monitor · 8
PDF
Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration
2002 · Dagmar Busse, Gudrun Würthwein, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 8
Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC)
2017 · AXEL WEIN, JUERGEN SIEBLER, et al. · Anticancer Research · 3
PDF
Dose-dependency of oxazaphosphorine pharmacokinetics.
1997 · D Busse, H K Kroemer · PubMed · 3
A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI – Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results
2021 · Axel Wein, Robert Stoehr, et al. · Oncology · 2
Efficacy and toxicity of second-line AIO plus irinotecan (IRI) after pretreatment with AIO plus oxaliplatin (L-OHP) in the sequential therapy of metastatic colorectal cancer (CRC).
2013 · Axel Wein, Frank Boxberger, et al. · Journal of Clinical Oncology · 2
Fortschritte in der Therapie von Tumorerkrankungen mit Zytostatika: Untersuchungen zur Hochdosistherapie mit Cyclophosphamid und zum Drug Targeting von Doxorubicin
1998 · Dagmar Busse, H. K. Kroemer, et al. · Pharmazie in unserer Zeit · 2
Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option
2016 · Axel Wein, Jürgen Siebler, et al. · Case Reports in Oncology · 1
PDF
Secondary metastasis resection after biomarker-stratified first-line treatment of metastatic colorectal carcinomaInterim analysis of the IVOPAK II study with a risk-benefit assessment of secondary metastatic resection
2026 · Axel Wein, Susanne Merkel, et al. · Oncology
Works count: 23
Citation count: 1,306
H-index: 12
I10-index: 13
Year
Topic
Type